Minireview

ARF-BP1 as a potential therapeutic target

D Chen¹, CL Brooks¹ and W Gu*¹,¹
¹Institute for Cancer Genetics, Department of Pathology, College of Physicians & Surgeons, Columbia University, 1150 St Nicholas Ave, New York, NY 10032, USA

In this review, we discuss the recent identification of ARF-BP1 (also known as Mule, UREB1, E3thione, LASU1, and HectH9). ARF-BP1, a HECT domain-containing E3 ubiquitin ligase, interacts with ARF and p53. Its ubiquitin ligase activity is inhibited by ARF. Inactivation of ARF-BP1 stabilised p53 and induced apoptosis. Notably, inactivation of ARF-BP1 also caused cell growth repression in p53-null cells and breast cancer cells with mutant p53. Thus, ARF-BP1 emerges as a novel therapeutic target against cancer regardless of p53 status.

Keywords: ARF-BP1; p53; ARF; Mdm2; therapeutic

The function of p53 as a transcription factor in the induction of cell growth arrest and apoptosis has been widely known and the importance of its role in tumour suppression has been firmly established. The activity of p53 as a sequence-specific transcription factor is highly regulated by other proteins through post-translational modifications, protein–protein interactions and protein stabilisation (Brooks and Gu, 2003; Harris and Levine, 2005). Therefore, study of regulators of p53 becomes very important in exploring cancer therapy (Bykov and Wiman, 2003; Vassilev et al, 2004).

Until recently, Mdm2, a RING finger E3 ubiquitin ligase, was thought to be the main regulator of p53 by ubiquitination and subsequent degradation by the 26S proteasome (Oren, 2003; Voudsen and Prives, 2005). ARF (known as p14ARF in humans and p19ARF in mouse) was originally identified as an alternative transcript of the Ink4a/ARF tumour-suppressor locus (Sherr, 2004). ARF exhibits tumour-suppressor functions, as demonstrated by the tumour susceptibility phenotype of p19ARF-deficient mice (Kamijo et al, 1997). The N-terminus region of ARF (N-ARF: residues 1–64), encoded by the unique 1b exon, is critical for ARF-mediated p53 activation as well as p53-independent ARF functions. The C-terminal region (C-ARF: residues 65–132), which is not conserved between human and mouse counterparts, is of uncertain function. ARF directly binds to and inactivates Mdm2 resulting in p53 stabilisation and p53-dependent apoptosis or cell cycle arrest (Quelle et al, 1995; Zhang et al, 1998). The ARF-Mdm2-p53 axis is undoubtedly an important component of ARF’s tumour-suppressor activity. However, a number of recent studies have demonstrated that ARF also possesses p53- and Mdm2-independent functions. For example, ARF can induce cell growth arrest in tumour cells that lack a functional p53 gene or its key transcriptional target p21 (Weber et al, 2000; Modestou et al, 2001; Korgaonkar et al, 2002; Eymin et al, 2003; Normand et al, 2005). Expression of ARF inhibits the proliferation of cells that are null for both p53 and Mdm2 (Weber et al, 2000). Moreover, mice lacking both ARF and p53 develop multiple primary tumours of a wider spectrum than those mice lacking either gene alone. In the same study, mice lacking p53, Mdm2, ARF were found to develop tumours at a higher frequency and of wider spectrum than those with mice lacking p53 and Mdm2 (Weber et al, 2000). Inactivation of ARF by hypermethylation was observed in human colorectal tumours having inactivated p53 (Esteller et al, 2001). Hence, ARF targets other proteins in addition to Mdm2. Recently, it has been reported that ARF interacts with B23 (nucleoplasmin), a nucleolar protein implicated in ribosomal biogenesis (Bertwistle et al, 2004). Moreover, ARF has been shown to associate with c-Myc and inhibit the expression of c-Myc-activated genes (Qi et al, 2004). Interestingly, ARF interacts with certain members of the E2F family of transcription factors (Martelli et al, 2001). All of these might in part explain the p53-independent function of ARF, but the mechanisms remain unclear.

ARF-BP1, a HECT E3 ubiquitin ligase, plays an important role in the mediation of p53 dependent and independent effects on ARF

In a recent study, a major protein band of ~500 kDa (named ARF-BP1) was purified from HA-ARF-Flag-expressing H1299 cells by mass spectrometric analysis (Chen et al, 2005). The C-terminal sequences of ARF-BP1 (also known as Mule, UREB1, E3thione LASU1 and HectH9) possess a HECT domain (4036–4374) (Adhikary et al, 2005; Chen et al, 2005; Liu et al, 2005; Zhong et al, 2005). ARF-BP1 also contains the ubiquitin-associated domain (UBA, 1318–54) and a WWE domain (1612–92). The former is a small sequence motif found in various proteins linked to the ubiquitination pathway such as the DNA repair protein Rad23 and the Cbl ubiquitin ligase. The latter may be involved in protein–protein interactions. ARF-BP1 mRNA is broadly expressed in various types of human tissue (Chen et al, 2005).

A region of ARF-BP1 (1015–4574) not including the N-terminus (1–1014) strongly bound the N-terminal domain of ARF. ARF and ARF-BP1 also interact with each other under physiological
conditions as shown by co-immunoprecipitations of H1299 cell lysates with z-ARF-BP1 or z-ARF (Chen et al., 2005). ARF-BP1 displays E3 enzymatic activity in an in vitro assay, and this self-ubiquitination activity was strongly repressed by ARF (Chen et al., 2005). Notably, ARF-BP1 inactivation by RNAi induces cell growth repression with G2/M arrest in p53-null cells H1299 and Saos-2, similar to that seen in response to ARF induction (Eymin et al., 2003; Chen et al., 2005; Normand et al., 2005). Based on our observation that ARF-BP1 is the major binding partner of ARF in p53-null cells, the ability of ARF to neutralise ARF-BP1 plays a critical contribution to the p53-independent antiproliferative effects of ARF (Chen et al., 2005; Shmuely and Oren, 2005). Future work is necessary to clarify the precise mechanism of ARF-BP1-mediated and p53-independent cell growth inhibition induced by ARF. As ARF-BP1 is a bona fide E3 ubiquitin ligase, it is likely that the p53-independent functions of ARF involve unidentified enzymatic substrates of ARF-BP1.

Surprisingly, ARF-BP1 can interact directly with the p53 protein and induces p53 ubiquitination. Significantly, ARF-BP1-mediated p53 ubiquitination was strongly repressed by ARF (Chen et al., 2005). Also, the N-terminal region of ARF retained full inhibition of ARF-BP1-mediated p53 ubiquitination whereas the C-terminal region showed no effect. This is consistent with the previous reports that N-terminal ARF has full functional responses (Weber et al., 1999; Midgley et al., 2000). RNAi-mediated knockdown of ARF-BP1 stabilised p53 and induced apoptosis (32.3%) in human osteosarcoma cells (U2OS). Similar results were achieved using different cell lines with wild-type p53, such as human breast carcinoma cells (MCF-7), human lung adenocarcinoma cells (A549) and normal human fibroblast cells (NHF-1) (Chen et al., 2005). An inverse correlation between ARF-BP1 and p53 expression in colorectal carcinoma samples has also been shown by immunofluorescence (Yoon et al., 2005). By overexpression, ARF can stabilise p53 in p53/Mdm2 double-null MEF cells. Moreover, the p53 stabilisation induced by ARF was clearly attenuated by further ARF-BP1 knockdown of these cells, suggesting that ARF-BP1 is critical for ARF-mediated p53 stabilisation in an Mdm2-independent manner (Chen et al., 2005).

In addition, two other recently identified proteins, Pirh2 and COP1, are also found to promote p53 degradation via the ubiquitin-proteasome pathway (Leng et al., 2003; Corcoran et al., 2004; Dornan et al., 2004). We tested the differential effects of the known E3 ligases on p53 stabilisation by RNAi knockdown (Chen et al., 2005). Depletion of Mdm2 stabilised p53 while depletion of either COP1 or Pirh2 had a modest effect. Remarkably, inactivation of ARF-BP1 strongly induced p53 stabilisation and activated p53-mediated transcription; among the known E3 ligases for p53, ARF-BP1 RNAi induced the highest levels of p21 and Bax, and exhibited similar effects to ARF overexpression. Hence, ARF-BP1 is a major E3 ubiquitin ligase for p53, and more importantly, is also a key mediator for ARF tumour-suppressor function.

It is now clear that ARF interacts with and regulates at least two distinct E3 ubiquitin ligases, Mdm2 and ARF-BP1, for their ubiquitination of p53 (den Besten et al., 2005). This is consistent with the previous evidence suggesting that ARF-mediated activation of p53 is more complicated than the simple ARF-Mdm2-p53 model. First, while the low levels of Mdm2 that are commonly observed in normal cells preferentially catalyse monoubiquitination of p53 (Li et al., 2003), ARF can not inhibit Mdm2-mediated monoubiquitination of p53 in vivo, although it can block p53 polyubiquitination (Xirodimas et al., 2001). Second, recent studies of p19ARF demonstrated that ARF is able to cause cell cycle arrest independent of Mdm2 relocalisation to nucleoli and p53 stabilisation (Llanos et al., 2001; Korgaonkar et al., 2002). Thus, a critical question raised is how ARF can efficiently stabilise p53 in normal cells with low levels of Mdm2, a situation where Mdm2 is not solely responsible for p53 degradation. Our results with ARF-BP1 suggest a novel pathway independent of Mdm2 for ARF-mediated p53 activation. ARF-BP1 was identified as a significant component of ARF-containing protein complexes and endogenous protein interaction between ARF-BP1 and ARF is easily detected in unstrressed cells. These two distinct pathways for ARF-mediated p53 activation allow for more precise control of p53, but also raise the question of their biological significance. For example, it is well established that Mdm2 plays a critical role in tumorigenesis. Protein overexpression and gene amplification of Mdm2 are found in various types of tumours (Michael and Oren, 2003). Thus, the ARF-Mdm2 pathway might be especially important in cells expressing high levels of Mdm2. Interestingly, we found that ARF-BP1 is highly expressed in 80% (16 out of 20) of breast cancer cell lines while the expression level of ARF-BP1 in normal breast cells (MCF-10A) is low, suggesting a potential role of ARF-BP1 in breast cancer tumorigenesis.

The importance of p53 in cancer development is illustrated by the fact that p53 is highly mutated in many different cancers. The mutations are found mainly in the specific DNA-binding core domain of p53-residues 98–292 (Sousi and Lozano, 2005). It may be interesting to deduce the functional consequence of ARF-BP1 reduction in cells expressing mutant p53. Significantly, inactivation of ARF-BP1 could also inhibit cell growth in cancer cells with mutant p53 (MDA-MB-468, Hs-578T) (Figure 1). Similar results were also found in other breast cancer cells with mutant p53 such as T47D, BT-549, MDA-MB-435, SK-BR-3.

ADDITIONAL TARGETS OF ARF-BP1/HectH9

It was recently reported that ARF-BP1 ubiquitinated Myc through a lysine 63-linked polyubiquitin chain (Adhikary et al., 2005). This ubiquitination does not cause Myc degradation (Adhikary et al., 2005), consistent with the absence of Myc stabilisation when ARF-BP1 is inactivated (Chen et al., 2005). However, the ubiquitination of Myc by ARF-BP1 significantly alters transcription properties of Myc. Depletion of ARF-BP1 downregulates Myc-dependent gene activation and represses cell proliferation induced by Myc. Similarly, depletion of ARF-BP1 by RNAi leads to growth arrest in HeLa cells, despite a high endogenous level of Myc expression (Adhikary et al., 2005). Thus, it appears that ARF-BP1 functionally
links Myc and ARF. ARF, ARF-BP1, and Myc can form a ternary complex since ARF and Myc bind each other directly (Qi et al., 2004). It is reasonable that the inhibition of ARF-BP1 by ARF could contribute at least in part to ARF-mediated inhibition of Myc transcriptional activation, although it has not been established yet that ARF inhibits Myc ubiquitination mediated by ARF-BP1. Myc seems to be one of the ARF-BP1 p53-independent substrates. The induction of ARF by Myc may serve as a negative feedback loop to limit excessive Myc functions.

Figure 2  The role of ARF-BP1. The important role of ARF-BP1 as a major ubiquitin ligase for p53 in an Mdm2-independent pathway. ARF-BP1 also functions as an E3 ubiquitin ligase for Myc and regulates the switch between the activated and repressed state of Myc protein. ARF-BP1 may have other substrates such as histones and Mcl-1. Induction of ARF by Myc resulting in inhibition of ARF-BP1 may serve as a negative feedback loop to limit excessive Myc functions.

ARF-BP1 as a potential therapeutic target
D Chen et al

unclear, although it is possible that ARF-BP1 differentially targets these proteins under different states of cell stress and/or other physiologic conditions. These other targets may somehow limit the therapeutic potential of ARF-BP1 in cancer therapy. In the future, it will be important to ascertain specific circumstances in which proteins like MCI-1 are activated, so that these situations can be avoided in treatments targeting the ARF-BP1-p53/myc pathway. Moreover, future work is necessary to uncover additional molecular substrates of ARF-BP1 as suggested by its large size (Shmueli and Oren, 2005).

ARF-BP1 as a therapeutic potential for cancer

Recently, numerous studies indicate that activating p53 is very important for the function of many cancer therapy drugs in vivo; p53-dependent apoptosis seems to have a major role for the efficiency of cancer chemotherapy in cancer cells expressing wild type p53. The negative regulation of p53 by ARF-BP1 has now been established (Gu et al., 1995; Chen et al., 2005). Based on our results that inactivation of ARF-BP1 expression activates p53 function, ARF-BP1-mediated negative regulation of p53 might be a very important target for cancer therapy. Thus, potential drugs that can downregulate ARF-BP1 protein levels or abrogate the ARF-BP1-p53 interaction in vivo may sensitize tumour cells. Similarly, agents that activate the p53 tumour-suppression pathway, including Nutlin and HLH18, small molecules that block the p53-Mdm2 interaction (Vassilev et al., 2004), and inhibit the E3 ubiquitin ligase activity of Mdm2, respectively, (Yang et al., 2005) are currently being tested for their potential use in cancer therapy. However, the utility of these agents is limited to tumours that maintain a functional p53 pathway, a significant restriction given that p53 is often inactivated by mutations. Since inactivation of ARF-BP1 could also induce growth arrest in p53-null or mutant p53 cells, at least partially through downregulation of Myc-target genes, inhibitors of ARF-BP1 should suppress tumour cell growth in a wide spectrum of tumour types. Therefore, ARF-BP1 may prove to be an especially valuable therapeutic target for a wider variety of cancer types.

REFERENCES

Adhikary S, Marinoni F, Hock A, Hullemen E, Popov N, Beier R, Bernard S, Quarto M, Capra M, Goettig S, Kogel U, Scheffner M, Helin K, Eilers M (2005) The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell 123: 409 – 421
Bertwistle D, Sugimoto M, Sherr CJ (2004) Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 24: 985 – 996
Brooks CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15: 164 – 171
Bykov VI, Wiman KG (2003) Novel cancer therapy by reactivation of the p53 apoptosis pathway. Ann Med 35: 458 – 465
Chen D, Kon N, Li M, Zhang W, Qin J, Gu W (2005) ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell 121: 1071 – 1083
Corcoran CA, Huang Y, Sheikh MS (2004) The p53 p53-linked wagen: COP1, Pirh2 and Mdm2 are found resisting apoptosis and growth arrest. Cancer Biol Ther 3: 721 – 725
den Besten W, Kuo ML, Williams RT, Sherr CJ (2005) Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle 4: 1593 – 1598
Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O’Rourke K, Koeppen H, Dixit VM (2004) The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429: 86 – 92
Esteller M, Gordon-Cardo C, Corn PG, Meltzer SJ, Pohar KS, Watkins DN, Capella G, Peinado MA, Matias-Guiu X, Prat J, Baylin SB, Herman JG (2001) p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 61: 2816 – 2821
Eymin B, Leduc C, Coll JL, Brambilla E, Gazzeri S (2003) p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 22: 1822 – 1835
Gu J, Dubner R, Fornace Jr AJ, Iadarola MJ (1995) UREB1, a tyrosine phosphorylated nuclear protein, inhibits p53 transactivation. Oncogene 11: 2175 – 2178
Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899 – 2908
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91: 649 – 659
Korgaonkar C, Zhao L, Modestou M, Quelle DE (2002) ARF function does not require p53 stabilization or Mdm2 relocalization. Mol Cell Biol 22: 196 – 206
Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S (2003) Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112: 779 – 791
Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W (2003) Mono- vs polyubiquitination: differential control of p53 fate by Mdm2. Science 302: 1972 – 1975

© 2006 Cancer Research UK
British Journal of Cancer (2006) 94 (11), 1555 – 1558
Liu Z, Oughtred R, Wing SS (2005) Characterization of E3Histone, a novel testis ubiquitin protein ligase which ubiquitinates histones. *Mol Cell Biol* 25: 2819 – 2831

Llanos S, Clark PA, Rowe J, Peters G (2001) Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. *Nat Cell Biol* 3: 445 – 452

Martelli F, Hamilton T, Silver DP, Sharpless NE, Bardeesy N, Rokas M, DePinho RA, Livingston DM, Grossman NE (2001) p19ARF targets certain E2F species for degradation. *Proc Natl Acad Sci USA* 98: 4455 – 4460

Michael D, Oren M (2003) The p53-Mdm2 module and the ubiquitin system. *Semin Cancer Biol* 13: 49 – 58

Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, Lane DP (2000) An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. *Oncogene* 19: 2312 – 2323

Modestou M, Puig-Antich V, Korgaonkar C, Eapen A, Quelle DE (2001) The alternative reading frame tumor suppressor inhibits growth through p21-dependent and p21-independent pathways. *Cancer Res* 61: 3145 – 3150

Normand G, Hemmati PG, Verdoodt B, von Haefen C, Wendt J, Guner D, May E, Dorken B, Daniel PT (2005) p14ARF induces G2 Cell Cycle Arrest in p53- and p21-deficient cells by down-regulating p34cdc2 kinase activity. *J Biol Chem* 280: 7118 – 7130

Oren M (2003) Decision making by p53: life, death and cancer. *Cell Death Differ* 10: 431 – 442

Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR (2004) p19ARF directly and differentially controls the functions of c-Myc independently of p53. *Nature* 431: 712 – 717

Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. *Cell* 83: 993 – 1000

Sherr CJ (2004) Principles of tumour suppression. *Cell* 116: 235 – 246

Shmueli A, Oren M (2005) Life, death, and ubiquitin: taming the mule. *Cell* 121: 963 – 965

Soussi T, Lozano G (2005) p53 mutation heterogeneity in cancer. *Biochem Biophys Res Commun* 331: 834 – 842

Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. *Science* 303: 844 – 848

Vousden KH, Prives C (2005) p53 and prognosis: new insights and further complexity. *Cell* 120: 7 – 10

Warr MR, Acoca S, Liu Z, Germain M, Watson M, Blanchette M, Wing SS, Shore GC (2005) BH3-ligand regulates access of MCL-1 to its E3 ligase. *FEBS Lett* 579: 5603 – 5608

Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP (2000) p53-independent functions of the p19(ARF) tumor suppressor. *Genes Dev* 14: 2358 – 2365

Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D (1999) Nucleolar Arf sequesters Mdm2 and activates p53. *Nat Cell Biol* 1: 20 – 26

Xirodimas D, Saville MK, Edling C, Lane DP, Lain S (2001) Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. *Oncogene* 20: 4972 – 4983

Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoski P, Kenten JH, Phillips AC, Weissman AM, Vousden KH (2005) Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. *Cancer Cell* 7: 547 – 559

Yoon SY, Lee Y, Kim JH, Chung AS, Joo JH, Kim CN, Kim NS, Choe IS, Kim JW (2005) Over-expression of human UREB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein. *Biochem Biophys Res Commun* 326: 7 – 17

Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the RB and p53 tumor suppression pathways. *Cell* 92: 725 – 734

Zhong Q, Gao W, Du F, Wang X (2005) Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. *Cell* 121: 1085 – 1095